Drugs Made In America Acquisition Corp.

Drugs Made In America Acquisition Corp. (Nasdaq: DMAA) is a blank-check company organized to pursue an acquisition in the domestic pharmaceutical and life sciences sector. The company filed an 8-K with the Securities and Exchange Commission on May 5, 2026, reporting a material corporate event. DMAA's stated acquisition mandate centers on domestic drug manufacturing and related healthcare businesses, a segment that has drawn dedicated SPAC vehicles in recent cycles. The SPAC's continued filing activity reflects active progress in its search for a combination target within the U.S. pharmaceutical space. Investors seeking the full DMAA filing record, sponsor details, and deal-stage analytics can access the complete dataset by signing up on SpacDesk.